猪伪狂犬病病毒疫苗株Bartha-K61在犬科动物体内的安全性评价及免疫实验

Safety evaluation and immunogenicity study about the vaccine strain Bartha-K61 of pseudorabies in canine

为了对猪伪狂犬病病毒(PRV)疫苗株Bartha-K61在犬科动物体内的安全性和免疫原性作出评价,通过3种免疫途径(肌肉注射、滴鼻免疫和口服免疫)对犬进行免疫(2mL,6×108PFU/mL),并在免疫结束后通过组织病理切片、免疫组化、临床表现、产仔性能、排泄物中病毒存留情况进行了检测。结果发现,在PRV易感器官内未发现病毒抗原,且疫苗接种犬体温正常,精神状态良好,产仔正常,无任何不良症状,排泄物中亦无病毒粒子残留;同时,通过对免疫后犬只的细胞免疫水平、体液免疫水平和中和试验的检测发现,3种免疫途径均可有效地刺激机体产生免疫应答,且中和抗体水平达到较高水平。从而证明,PRV Bartha-K61在犬科动物体内安全有效,为以PRV为载体表达犬科动物疫病的抗原基因重组活载体疫苗的研制提供了科学依据。

In order to estimate safety and immunogenicity for vaccine strain Bartha K61 of pseudorabies in canine,we immunized dogs by three routes （intramuscular injection,intranasal vaccination and oral vaccination） with 2 mI. vaccine（6 × 10^8 PFU/mL）. After a trial was ended, a serial indices including pathological section,immunohistochemistry,clinical manifestation, birth performance, viral persistence in excreta were abserved. The resutls showed that no antigen existed in sensitive organs, body temperature was normal, mental state and birth was well, no virion was found in excreta;and that effective immune response was induced by the three immune routes and neutralization antibody arrived a higher level as compared with the non-immunized group. The Bartha-K61 voccine was domonstrated to be of safety for dogs and, accordingly, provided a scientific basis for development of recombinant live vaccine that expressed the antigens using the PRV as the vector.